ALTERNATING CHEMORADIOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL PLUS BLEOMYCIN BY CONTINUOUS INFUSION FOR LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE

被引:38
|
作者
AZLI, N
ARMAND, JP
RAHAL, M
WIBAULT, P
BOUSSEN, H
ESCHWEGE, F
SCHWAAB, G
GASMI, J
BACHOUCHI, M
CVITKOVIC, E
机构
[1] INST GUSTAVE ROUSSY, UNITE LA GRANGE VILLEJUIF, F-77176 VILLEJUIF, FRANCE
[2] INST SALAH AZAIZ, TUNIS, TUNISIA
[3] CTR ANTI CANC BENBADIS, CONSTANTINE, ALGERIA
关键词
D O I
10.1016/0959-8049(92)90005-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom. From February 1986 to November 1987 30 consecutive patients with very advanced local disease were entered in a programme with chemotherapy-radiotherapy (CT-RT) alternation after a thorough work-up to eliminate the possibility of distant metastases. Protocol: two cycles of cisplatin 100 mg/m2 day 1, bleomycin 15 mg intravenously day 1 and 16 mg/m2 per day by continuous infusion days 1-5; 5-fluorouracil (5-FU) 650 mg/m2 per day by continuous infusion days 1-5 4 weeks apart. This was followed by two series of high-energy radiotherapy, 35 Gy/3.5 weeks, with a third chemotherapy cycle in between. 27 men and 3 women were treated, the median age was 37 years (range 17-71) and the mean WHO performance status was 1 (range 0-3). TNM classification: 15 T4, 9 T3, 6 T2, 28 N3 and 2 N2c. 18 patients had nodes larger than 8 cm and 24 had bulky bilateral cervical nodes. Toxicity for this protocol was moderate, nausea and vomiting being the main side-effects. Results after two CT cycles were 3 complete responses (CR; 10%), 22 partial responses (PR; 73%), 2 disease stabilisations, 2 progressions, and 1 patient inevaluable. Of the 30 patients, 27 patients completed the CT-RT protocol, 2 patients died before radiotherapy and 1 refused treatment after 2 days on protocol. 25 patients were in CR 3 months after the end of radiotherapy. As of August 1991, with a median follow-up of 55 months (range 43-63), there are 17 patients alive, 2 of them with active disease and 15 are NED (2 after salvage therapy).
引用
收藏
页码:1792 / 1797
页数:6
相关论文
共 50 条
  • [1] Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type
    Taamma, A
    Fandi, A
    Azli, N
    Wibault, P
    Chouaki, N
    Hasbini, A
    Couteau, C
    Armand, JP
    Cvitkovic, E
    CANCER, 1999, 86 (07) : 1101 - 1108
  • [2] CHEMOTHERAPY WITH CISPLATIN AND CONTINUOUS-INFUSION OF 5-FLUOROURACIL AND BLEOMYCIN FOR RECURRENT AND METASTATIC NASOPHARYNGEAL CARCINOMA IN TAIWAN
    SU, WC
    CHEN, TY
    KAO, RH
    TSAO, CJ
    ONCOLOGY, 1993, 50 (04) : 205 - 208
  • [3] Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma
    Sol, Eui-Sok
    Lee, Tae Sung
    Koh, Suk Bong
    Oh, Hun Kyu
    Ye, Gi Won
    Choi, Youn Seok
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2009, 20 (01) : 28 - 34
  • [4] PROLONGED CONTINUOUS-INFUSION CISPLATIN AND 5-FLUOROURACIL WITH RADIATION FOR LOCALLY ADVANCED-CARCINOMA OF THE VULVA
    EIFEL, PJ
    MORRIS, M
    BURKE, TW
    LEVENBACK, C
    GERSHENSON, DM
    GYNECOLOGIC ONCOLOGY, 1995, 59 (01) : 51 - 56
  • [5] Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
    Chen, Y.
    Ye, J.
    Zhu, Z.
    Zhao, W.
    Li, L.
    Fan, M.
    Wu, C.
    Tang, H.
    Xu, G.
    Lin, Q.
    Li, J.
    Xia, Y.
    Yunhai, L.
    Zhou, J.
    Zhao, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S28 - S28
  • [6] Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma
    Dechaphunkul, Tanadech
    Pruegsanusak, Kowit
    Sangthawan, Duangjai
    Sunpaweravong, Patrapim
    HEAD & NECK ONCOLOGY, 2011, 3
  • [7] Gemcitabine/Cisplatin versus docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy in locally advanced nasopharyngeal carcinoma
    Gharib, Fatma
    Elkady, Asma M.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4506 - 4513
  • [8] Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type
    Fandi, A
    Taamma, A
    Azli, N
    Bachouchi, M
    Yanes, B
    Armand, JP
    Cvitkovic, E
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1997, 19 (01): : 41 - 47
  • [9] CHEMOTHERAPY OF METASTATIC AND OR RECURRENT UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA WITH CISPLATIN, BLEOMYCIN, AND FLUOROURACIL
    BOUSSEN, H
    CVITKOVIC, E
    WENDLING, JL
    AZLI, N
    BACHOUCHI, M
    MAHJOUBI, R
    KALIFA, C
    WIBAULT, P
    SCHWAAB, G
    ARMAND, JP
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) : 1675 - 1681
  • [10] CONCURRENT CHEMORADIOTHERAPY WITH WEEKLY 5-FLUOROURACIL PLUS CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER
    Lee, Y. J.
    Lee, C. G.
    Hong, S. J.
    Kim, Y. T.
    Kim, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 222 - 222